trastuzumab
trastuzumab is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand names including Ontruzant, OGIVRI. Available dosage forms: injection, powder, lyophilized, for solution, liquid, solution, kit.
Drug details
- Generic Name
- trastuzumab
- Brand Names
- Ontruzant, OGIVRI
- Application Number
- BLA761100
- Sponsor
- Organon LLC
- NDC Codes
- 6
- Dosage Forms
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, LIQUID, SOLUTION, KIT
- Routes
- INTRAVENOUS
- Active Ingredients
- TRASTUZUMAB, TRASTUZUMAB-QYYP
Indications and Usage
1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Herceptin is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin [see Dosage and Administration (2.2) ] . 1.2 Metastatic Breast Cancer Herceptin is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin [see Dosage and Administration (2.2) ] . 1.3 Metastatic Gastric Cancer Herceptin is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin [see Dosage and Administration (2.2) ] .